Rise Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Rise Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-64	Closed	-$870	–	169
2025 Q3	$870	Buy	+64	New	+$602	﹤0.01%	1298

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Rise Advisors's AMLX Position: Q4 2025 in Review

Rise Advisors sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2025, closing a stake of 64 shares — an estimated $870 sold.

Rise Advisors first reported a position in AMLX in Q3 2025 and held it in 1 quarter. The position peaked at $870 in Q3 2025. 179 funds tracked by Wall St. Rank hold AMLX as of Q4 2025.

Rise Advisors reported no remaining Amylyx Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 64 Amylyx Pharmaceuticals shares in Q4 2025, an estimated $870.
Rise Advisors first reported a position in Amylyx Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Rise Advisors's Amylyx Pharmaceuticals position peaked at $870 in Q3 2025.
179 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.